<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="78752">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01659346</url>
  </required_header>
  <id_info>
    <org_study_id>ILBS-HCC-01</org_study_id>
    <nct_id>NCT01659346</nct_id>
  </id_info>
  <brief_title>Non-selective Beta Blockers Versus EVL for Primary Prophylaxis of Esophageal Variceal Bleeding in Patients With Hepatocellular Carcinoma With Portal Vein Tumour Thrombosis.</brief_title>
  <official_title>A Prospective Randomized Controlled Trial Comparing Non-selective Beta Blockers Versus EVL for Primary Prophylaxis of Esophageal Variceal Bleeding in Patients With Hepatocellular Carcinoma With Portal Vein Tumour Thrombosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Liver and Biliary Sciences, India</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute of Liver and Biliary Sciences, India</source>
  <oversight_info>
    <authority>India: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Every patient with HCC with main portal vein thrombosis will be screened for presence of
      large esophageal varices and will be randomised between non-selective beta blocker versus
      primary endoscopic variceal ligation. They will be followed to assess the rate of reduction
      of index bleed rate as well as survival difference between the groups.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>First Variceal Bleeding</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure related complications.</measure>
    <time_frame>2 Years</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction   of risk of bleeding by 50 %</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <condition>Hepatocellular Carcinoma With Portal Vein Thrombosis</condition>
  <arm_group>
    <arm_group_label>Endoscopic Variceal Ligation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Endoscopic Variceal Ligation every 3 weeks till eradication</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Carvedilol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Carvedilol 3.125mg BD increased after 1 week to reach 6.25mg BD</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Endoscopic Variceal Ligation</intervention_name>
    <description>Endoscopic Variceal Ligation every 3 weeks till eradication.</description>
    <arm_group_label>Endoscopic Variceal Ligation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carvedilol</intervention_name>
    <description>Carvedilol 3.125mg BD increased after 1 week to reach 6.25mg BD</description>
    <arm_group_label>Carvedilol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients of cirrhosis with Hepatocellular carcinoma and portal vein thrombosis

          -  Presence of large oesophageal varices or small with high risk

        Exclusion Criteria:

          -  Any contra-indication to beta-blockers

          -  Any Endoscopic Variceal Ligation or Sclerotherapy within last 3 months

          -  High risk gastric varices

          -  Any past history of Transhepatic Intrajugular Portosystemic Shunt or surgery for
             portal hypertension

          -  Significant cardio or pulmonary co-morbidity

          -  Any extrahepatic malignancy

          -  Patients with past history of variceal bleed

          -  Patients with non-tumor portal vein thrombosis

          -  Refusal to participate in the study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr SM Shasthry, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Liver and Biliary Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dr SM Shasthry, MD</last_name>
    <phone>011-46300000</phone>
    <email>shasthry@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dr Ankit Bhardwaj</last_name>
    <phone>011-46300000</phone>
    <phone_ext>1032</phone_ext>
    <email>bhardwaj.ankit3@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institute of Liver and Biliary Sciences</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110070</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr SM Shasthry, MD</last_name>
      <phone>011-46300000</phone>
      <email>shasthry@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Dr Ankit Bhardwaj</last_name>
      <phone>011-46300000</phone>
      <phone_ext>1032</phone_ext>
      <email>bhardwaj.ankit3@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 16, 2013</lastchanged_date>
  <firstreceived_date>August 4, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adrenergic beta-Antagonists</mesh_term>
    <mesh_term>Carvedilol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
